For patients with osteoporosis, injectable treatment and 1 time/year refers to MIGUDA. The main component of these drugs is zoledronic acid, which belongs to the bisphosphonate class of drugs and is effective in inhibiting bone resorption and destruction. These drugs are mainly used for osteoporosis in older menopausal women, or for primary osteoporosis in older patients. It is important to conduct a thorough evaluation of these patients before using the drug. This is because these drugs can lead to a number of complications after application, such as reactions in the heart, liver, kidneys, and other areas. Therefore, the doctor will only administer the drug after passing the relevant tests to confirm that the patient can tolerate the drug, and the patient will also be closely monitored after the use of such drugs, such as cardiac monitoring. After such treatment, the patient also needs to cooperate with the doctor for regular calcium and vitamin D supplementation and proper functional exercise.